2023 Review
Don't Look Back in Anger
The biopharma sector spent much of 2023 wondering whether investor sentiment could get any worse. As new depths were plumbed in October the answer appeared to be yes.
Foreword
IPOs Fizzle Out In The Fourth Quarter
VC Fundraising Fell In Q4 But There Are Glimmers Of Hope For 2024
Biopharma M&A Volume, Value Bounced Back Significantly In Q4
Contact us for more information